Ligand UK Development Limited
Records under this name other than the patents Ligand UK Development Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
Back to Ligand UK Development Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,163,747 | Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-Isopropyl-PHENYL)-4-(4-Morpholin-4-Ylmethyl-PHENYL)-ISOXAZOLE-3-Carboxylic Acid Ethylamide and Formulations Comprising These Forms Formerly held In force · High confidence | In force | High confidence | |
| US 7,671,059 | 2-Amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones Formerly held Term ended Term ended Sep 28, 2026 · High confidence | Term ended | Term ended Sep 28, 2026 | High confidence |
| US 8,487,095 | Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms Formerly held Lapsed on the fee record Ended Jul 16, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 16, 2025 | From the USPTO record |
| US 8,507,480 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Term ended Dec 25, 2024 · From the USPTO record | Term ended | Term ended Dec 25, 2024 | From the USPTO record |
| US 7,705,027 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Term ended Sep 24, 2024 · From the USPTO record | Term ended | Term ended Sep 24, 2024 | From the USPTO record |
| US 8,450,310 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Ended no later than Feb 9, 2024 · From the USPTO record | Term ended | Ended no later than Feb 9, 2024 | From the USPTO record |
| US 9,718,793 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Ended no later than Feb 9, 2024 · From the USPTO record | Term ended | Ended no later than Feb 9, 2024 | From the USPTO record |
| US 10,413,550 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Ended no later than Feb 9, 2024 · From the USPTO record | Term ended | Ended no later than Feb 9, 2024 | From the USPTO record |
| US 11,234,987 | Isoxazole compounds as inhibitors of heat shock proteins Term ended Ended no later than Feb 9, 2024 · From the USPTO record | Term ended | Ended no later than Feb 9, 2024 | From the USPTO record |
| US 7,141,575 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists Term ended Term ended May 15, 2022 · From the USPTO record | Term ended | Term ended May 15, 2022 | From the USPTO record |